Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01085643 · ClinicalTrials.gov registry record · NA

Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)

A NA study, sponsored by Cedars-Sinai Medical Center.

Completed
Registry status
NA
Development phase
4
Enrollment target

NCT01085643: Completed NA study, sponsored by Cedars-Sinai Medical Center.

NCT01085643 is a NA study that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 4 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01085643, a NA study, has completed, sponsored by Cedars-Sinai Medical Center.

COMPLETED
Registry status
NA
Development phase
4 participants
Enrollment target

Study Summary

Irritable Bowel Syndrome (IBS) is a common disorder, defined by symptom-based diagnostic criteria. The pathogenesis is multifactorial and gut motor dysfunction is considered to be a contributing factor. Changes in motor patterns in the small bowel in IBS patients are quantitative rather than qualitative with no distinct patterns to distinguish patients from healthy individuals. Changes in motor patterns can affect transit of bowel contents. Indeed, variation in intestinal transit was reported in patients with IBS. Lubiprostone is a novel agent that is Food and Drug Administration (FDA) approved for the treatment of chronic constipation. More recently 2 randomized double-blind, placebo-controlled trials showed the drug to be effective in relieving symptoms in patients with constipation-predominant Irritable Bowel Syndrome (C-IBS), resulting in approval for female patients with C-IBS at a dose of 8 micrograms twice a day. The investigators hypothesize that lubiprostone works not just as a laxative, but by actually altering motility patterns in the small intestine of female patients with C-IBS. These alterations can be measured through High Resolution Manometry (HRM), a new technique that uses catheters with multiple closely spaced sensors and special software that uses color schemes to portray a pressure gradient. This technique allows a detailed assessment of the direction and spread of contractions. The investigators would like to use HRM to see if lubiprostone affects intestinal contractions by giving blinded participants lubiprostone and placebo while they are undergoing High Resolution Manometry and seeing if any changes in contractions occur. Participants will be recruited from investigator's clinic. If interested, potential subjects will be provided with a copy of the consent form for review. Patients will be informed that after they have had an opportunity to review the consent form, they may contact the study team to further discuss the research and address

Primary Outcome

Pressure waves are considered to represent contractions if the rise in intraluminal pressure is \>10mmHg above the baseline. They are considered propagating if they are recorded in more than one channel and occur within a time frame that allowed a minimal velocity of 0.7cm/sec and maximum velocity of 4cm/sec. All contractions, their direction (antegrade, stationary or retrograde) and the length of spread will be determined for each sequence at baseline (after taking Placebo)and within the follow

Interventions

  • DRUG Placebo
  • DRUG Lubiprostone

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2010-03
Est. Completion 2010-12
Phase NA
Cedars-Sinai Medical Center

339 total trials

What the finished NCT01085643 record still lists

NCT01085643 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01085643 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01085643 about?

NCT01085643 is a clinical study titled "Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)". Irritable Bowel Syndrome (IBS) is a common disorder, defined by symptom-based diagnostic criteria. The pathogenesis is multifactorial and gut motor dysfunction is considered to be a contributing factor. Changes in motor patterns in the small bowel in IBS patients are quantitative rather than qualita...

What is the current status of trial NCT01085643?

This trial is currently completed. It is a NA study. The enrollment target is 4 participants. The study started on 2010-03. Estimated completion is 2010-12.

What interventions are being tested in trial NCT01085643?

The interventions under investigation include: Placebo (DRUG), Lubiprostone (DRUG).

Who is sponsoring clinical trial NCT01085643?

This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01085643's enrollment target sits among peer trials

4 1996th of 2000 higher than 5 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01085643, the US trial registry maintained by the National Library of Medicine. NCT01085643 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.